Similarly, the PRMT5 gene has been implicated in the development of chemoresistance; conversely, its inhibition renders pancreatic cancer cells more susceptible to gemcitabine, a commonly used first‐ or second‐line chemotherapeutic agent [249]. This evidence concerns the gene PRMT5 and pancreatic neoplasm.